Annually, the European Academy of Cancer Sciences (EACS), a prestigious independent advisory body of leading oncologists and cancer researchers, awards Fellowship to scientists with exceptional achievements in oncology. At the end of 2025, CNAG’s Director, Ivo Gut, was elected as a Fellow in the area of genomics, proteomics and other omics technologies, recognising his outstanding contributions to cancer research.

 

 
 
In the words of CNAG’s Director: "I am truly honoured to be elected as a Fellow of the European Academy of Cancer Sciences. This recognition reflects not only my work, but also the dedication and expertise of all the teams at CNAG. I look forward to contributing to the Academy’s mission of advancing cancer research and improving patient care across Europe."
 
 
 
Dr Gut has dedicated his career to advancing genomics and bioinformatics for cancer. He coordinated the sequencing for the Spanish contribution to the International Cancer Genome Consortium, which led to the identification of key mutations in chronic lymphocytic leukaemia. He has also contributed to EU-funded projects including RD-Connect, EASI-GENOMICS, and READNA, and pioneered technologies such as nanopore sequencing, single-cell genomics, and the Genome-Phenome Analysis Platform (GPAP), supporting precision medicine and translational cancer research.
 
 
 
Being elected to the EACS is a major step for CNAG, recognising its involvement in cutting-edge cancer research. The Academy provides evidence-based guidance to support policies for the prevention, management, and palliation of cancer in Europe, and currently counts over 270 Fellows from across Europe and beyond.